Rituximab with steroids or rituximab alone for membranous kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- Your kidney biopsy confirmed primary membranous nephropathy
- You tried an ACE inhibitor or ARB for at least 3 months (unless you couldn’t tolerate it or had specific reasons your clinician ruled it out)
- Your urine protein is still high, and your kidney filtration is not too low (eGFR at least 30)
- If you are female, you must be postmenopausal or using effective contraception, not pregnant or planning pregnancy
- You have not previously used rituximab, steroids, certain immune-suppressing drugs, or related treatments before this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This study tests a new drug called JMT601 for people with primary membranous nephropathy, a kidney condition that causes protein in the urine. The goal is to see if JMT601 is safe and effective in reducing protein loss and protecting kidney function.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.